ORIGINAL RESEARCH

Hereditary risk factors for uterine leiomyoma: a search for marker SNPs

Svirepova KA1, Kuznetsova MV1, Sogoyan NS1, Zelensky DV2, Lolomadze EA1, Mikhailovskaya GV1, Mishina ND1, Donnikov AE1, Trofimov DYu1
About authors

1 Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Moscow, Russia

2 Valuyki Central Hospital, Valuyki, Russia

Correspondence should be addressed: Ksenia A. Svirepova
Akademika Oparina, 4, Moscow, 117997; ur.xednay@iwsesk

About paper

Funding: this study was part of the State Assignment (2019) on the Improved management of patients with benign reproductive system neoplasms with hi-tech diagnostic imaging techniques and molecular panels for predicting the progression and relapse of the disease.

Compliance with ethical standards: the study was approved by the Ethics Committee of Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology. Informed consent was obtained from all participants.

Author contribution: Svirepova KA analyzed the literature, carried out the research and wrote the manuscript with input from all authors; Kuznetsova MV carried out the research and wrote the manuscript with input from all authors; Sogoyan NS collected tissue samples and documented them in the biobank’s register; Zelensky DV collected tissue samples for research; Lolomadze EA, Mikhailovskaya GV helped with the laboratory part of the research; Mishina ND performed statistical analysis; Donnikov AE, Trofimov DYu supervised the study and revised the manuscript.

Received: 2020-02-05 Accepted: 2020-02-19 Published online: 2020-02-29
|
Table 1. Oligonucleotide primers for sequencing genome regions containing the analyzed polymorphisms
Table 2. The list of candidate polymorphisms and genes in which they are located
Table 3. Allele frequency distribution for the studied polymorphisms in the control group, subgroup Ia (women with a family history of the disease) and the main group (women with uterine leiomyomas)
Table 4. Allele frequency distribution for the studied polymorphisms in the control group, subgroup 1b (women with no family history of the disease) and the main group of patients with uterine leiomyomas